Editorial

Split Viewer

Blood Res 2015; 50(4):

Published online December 31, 2015

https://doi.org/10.5045/br.2015.50.4.187

© The Korean Society of Hematology

Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea

Seok Jin Kim, M.D. Ph.D.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

  1. Park, HJ, Park, EH, Jung, KW, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol, 2012;47;28-38.
    Pubmed
  2. Lee, S, Kim, MJ, Kim, JS, et al. Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Res, 2015;50;242-247.
  3. Suh, C, Kim, WS, Kim, JS, Park, BB. Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. Blood Res, 2013;48;171-177.
    Pubmed
  4. Lee, GW, Go, SI, Kim, SH, et al. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma, 2015;56;1020-1026.
    Pubmed
  5. Yhim, HY, Kim, JS, Kang, HJ, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer, 2012;131;235-243.
    Pubmed
  6. Kim, YR, Kim, JS, Min, YH, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol, 2012;5;49.
    Pubmed
  7. Oh, SY, Kim, WS, Kim, JS, et al. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). Int J Hematol, 2012;96;631-637.
    Pubmed
  8. Oh, SY, Kim, WS, Kim, JS, et al. Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study. Acta Haematol, 2012;127;100-104.
    Pubmed
  9. Yhim, HY, Kang, HJ, Choi, YH, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer, 2010;10;321.
    Pubmed

Article

Editorial

Blood Res 2015; 50(4): 187-188

Published online December 31, 2015 https://doi.org/10.5045/br.2015.50.4.187

Copyright © The Korean Society of Hematology.

Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea

Seok Jin Kim, M.D. Ph.D.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    References

    1. Park, HJ, Park, EH, Jung, KW, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol, 2012;47;28-38.
      Pubmed
    2. Lee, S, Kim, MJ, Kim, JS, et al. Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Res, 2015;50;242-247.
    3. Suh, C, Kim, WS, Kim, JS, Park, BB. Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. Blood Res, 2013;48;171-177.
      Pubmed
    4. Lee, GW, Go, SI, Kim, SH, et al. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma, 2015;56;1020-1026.
      Pubmed
    5. Yhim, HY, Kim, JS, Kang, HJ, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer, 2012;131;235-243.
      Pubmed
    6. Kim, YR, Kim, JS, Min, YH, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol, 2012;5;49.
      Pubmed
    7. Oh, SY, Kim, WS, Kim, JS, et al. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). Int J Hematol, 2012;96;631-637.
      Pubmed
    8. Oh, SY, Kim, WS, Kim, JS, et al. Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study. Acta Haematol, 2012;127;100-104.
      Pubmed
    9. Yhim, HY, Kang, HJ, Choi, YH, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer, 2010;10;321.
      Pubmed
    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download